Status:
COMPLETED
The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
Lead Sponsor:
University of Aarhus
Conditions:
Growth Hormone Deficiency
Eligibility:
MALE
19-71 years
Phase:
NA
Brief Summary
In the present double blind, placebo-controlled, parallel study we evaluated the impact of 12 weeks thiazolidinedione (TZD) administration on basal and insulin-stimulated substrate metabolism in growt...
Detailed Description
In human subjects GH (Growth Hormone) acutely antagonises the effects of insulin on glucose uptake in skeletal muscle and increases the hepatic glucose production of humans. This has clinical implicat...
Eligibility Criteria
Inclusion
- Growth hormone replaced (minimum 6 months) growth hormone deficient men
- Age over 18 years
Exclusion
- Ischemic coronary disease, defined by EF\<0.6, former myocardial infarction, angina pectoris or actual treatment of cardiac insufficiency
- Actual or former malignancy, except intracranial neoplasia that caused the participants pituitary disease, provided that there was clinical evidence for permanent remission
- Blood donation within 6 months
- Excessive alcohol consumption
- Known allergic reaction from contents of test drug
- Radioactive radiation exposure in terms of treatment or study enrollment within one year
- Liver insufficiency
- Insulin treatment
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00459940
Start Date
September 1 2004
End Date
March 1 2006
Last Update
April 13 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Department M, The Medical Research Laboratories, Aarhus University Hospital
Aarhus C, Denmark, 8000